IXICO Stock

IXICO EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of IXICO (IXI.L) as of Aug 20, 2026 is -3.22. In the previous year, EV/EBIT (Enterprise Value to EBIT) was -3.82 — a change of -15.66% (higher).

EV/EBIT

-3.22

YoY

-15.66%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of IXICO is 2026 -3.22 . EV/EBIT (Enterprise Value to EBIT) of IXICO was 2025 -3.82 . It decreases by -15.66% higher compared to the previous year.

The IXICO EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PRICE-TO-EBIT
Date
PRICE-TO-EBIT
Jan 1, 2019
71.37 base
Jan 1, 2020
34.38 base
Jan 1, 2021
27.01 base
Jan 1, 2022
14.22 base
Jan 1, 2023
-4.19 base
Jan 1, 2024
-2.64 base
Jan 1, 2025
-4.12 base
Jan 1, 2026 (e)
-2.43 base
YEARPRICE-TO-EBIT
2026 est -2.43
2025 -4.12
2024 -2.64
2023 -4.19
2022 14.22
2021 27.01
2020 34.38
2019 71.37
2018 -6.02
2017 -4.17
2016 -2.15
2015 -2.48
2014 -1.99
2013 -0.65
2012 -0.46
2011 -0.37
2010 -0.53
2009 -0.29
2008 -0.15
2007 -0.12
2006 -0.19
Access this data via the Eulerpool API

IXICO Valuation

Details

Historical Valuation Multiples

Price-to-Earnings Ratio (P/E)

The P/E ratio divides IXICO's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates IXICO's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots IXICO's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if IXICO grows earnings faster than its peers.

IXICO Stock analysis

What does IXICO do? IXICO PLC is a leading company in the field of digital biomarker and data services in clinical development. The company was originally founded in London in 2004 and has since had a successful history in neurology and psychiatry research. IXICO's core competency lies in developing and commercially implementing innovative solutions in the field of digital biomarker analysis, data capture, and processing. Through the use of advanced image analysis, structural analysis, and cognitive assessment technologies, IXICO enables effective clinical development of drugs and therapies, particularly in the areas of neurological and psychiatric disorders. IXICO is organized into three main divisions: Digital Healthcare Analytics (DHA), Data Analytics Services (DAS), and Clinical Trial Technology Solutions (CTTS). Each division includes its own products and services tailored to meet the specific requirements and needs of customers. The Digital Healthcare Analytics division focuses on developing biomarker-based clinical software-as-a-service (SaaS) solutions. These are used for monitoring and diagnosing neurological disorders such as Alzheimer's, Parkinson's, and schizophrenia. The solutions developed are tailored to the needs of clinics, research institutions, and biopharmaceutical companies and significantly contribute to the improvement of patient analysis and treatment. The Data Analytics Services division includes a wide range of services for data capture, processing, and analysis. This includes, for example, image and data analysis of clinical data, support for sponsors in data management and study monitoring, as well as consulting and training services. The purpose of this division is to help sponsors work in compliance with regulatory requirements and best practices in the pharmaceutical industry. IXICO's Clinical Trial Technology Solutions division offers a range of technology solutions to support the clinical research of pharmaceutical and biotechnology companies. This includes software solutions such as Neurostatus.net, a neurostatus toolkit for digital assessment of neurological patients, and TrialTracker, a SaaS solution that supports sponsors in the planning and conduct of studies. With its pioneering products and services, IXICO has numerous customers worldwide, including large pharmaceutical and biotech companies. The company also has partnerships with some of the most renowned academic institutions in Europe and North America and is proud to have been part of some of the most significant clinical studies in the field of neurology in recent years. Under the leadership of founder and CEO Derek Hill, IXICO has built an experienced and highly qualified team of scientists and industry experts over the years. The employees come from a variety of disciplines and industries and work closely together to develop innovative solutions and meet customer needs. The company expects to continue successfully focusing on the development of technology-based solutions in clinical research in the future. IXICO is one of the most popular companies on Eulerpool.

Frequently Asked Questions about IXICO stock

EV/EBIT (Enterprise Value to EBIT) of IXICO is -3.22 in 2026.

EV/EBIT (Enterprise Value to EBIT) of IXICO changed from -3.82 to -3.22, representing a -15.66% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) IXICO since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s IXICO with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — IXICO

All Key Metrics — IXICO